Cargando…

Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection

Ceftibuten-ledaborbactam etzadroxil is a cephalosporin-boronate β-lactamase inhibitor prodrug combination under development as an oral treatment for complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales producing serine β-lactamases (Ambler class A, C, and D). In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karlowsky, James A., Wise, Mark G., Hackel, Meredith A., Pevear, Daniel C., Moeck, Greg, Sahm, Daniel F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664860/ https://www.ncbi.nlm.nih.gov/pubmed/36286518 http://dx.doi.org/10.1128/aac.00934-22

Ejemplares similares

In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program
por: Karlowsky, James A., et al.
Publicado: (2023)

In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales
por: Karlowsky, James A., et al.
Publicado: (2022)

1293. In vitro Activity of Ceftibuten in Combination with VNRX-5236 against Clinical Isolates of Enterobacterales from Urinary Tract Infections Collected in 2018-2020
por: Hackel, Meredith, et al.
Publicado: (2021)

Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases
por: Chatwin, Cassandra L., et al.
Publicado: (2021)

2128. In Vitro Activity of Ceftibuten-Avibactam and Comparator Agents Against Resistant Enterobacterales from UTIs Collected Globally as Part of the ATLAS Surveillance Program, 2022
por: Hackel, Meredith, et al.
Publicado: (2023)

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
por: Karlowsky, James A., et al.
Publicado: (2022)

1253. Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Clinical Isolates of Enterobacterales from 2018-2020 Global Surveillance
por: Hackel, Meredith, et al.
Publicado: (2021)

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
por: Hamrick, Jodie C., et al.
Publicado: (2020)

2150. In Vitro Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018-2021
por: Wise, Mark G, et al.
Publicado: (2023)

In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019
por: Wise, Mark G., et al.
Publicado: (2023)

Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015‒2020
por: Wise, Mark G., et al.
Publicado: (2023)

203. Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Pseudomonas aeruginosa from a Global 2018-2020 Surveillance Collection
por: Hackel, Meredith, et al.
Publicado: (2021)

Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model
por: Lasko, Maxwell J., et al.
Publicado: (2021)

2129. Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Isolates from the United States 2018-2021
por: Hackel, Meredith, et al.
Publicado: (2023)

1055. ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236
por: Mack, Andrew R, et al.
Publicado: (2021)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

1567. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Multidrug-Resistant Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2016-2018
por: Kazmierczak, Krystyna, et al.
Publicado: (2020)

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020
por: Karlowsky, James A., et al.
Publicado: (2023)

The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales
por: Lomovskaya, Olga, et al.
Publicado: (2022)

1718. In Vitro Activity of Imipenem/Relebactam against Class C β-lactamase-Positive Enterobacterales in the Asia/Pacific Region: SMART 2018-2020
por: Lob, Sibylle, et al.
Publicado: (2022)

1565. In Vitro Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Collected from Patients with Skin and Skin Structure Infections: ATLAS Global Surveillance Program 2012-2018
por: Hackel, Meredith, et al.
Publicado: (2020)

1566. In vitro Activities of Ceftaroline and Comparator Agents against Gram-positive Bacterial Pathogens Causing Blood Stream Infections in a Global Population: ATLAS Surveillance Program 2012-2018
por: Hackel, Meredith, et al.
Publicado: (2020)

1582. In Vitro Activity of Ceftolozane/Tazobactam against Enterobacterales and Pseudomonas aeruginosa Isolates from Geriatric Patients in the Asia/Pacific region – SMART 2016-2018
por: Lob, Sibylle, et al.
Publicado: (2020)

1263. Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in a Hollow Fiber Infection Model (HFIM)
por: Avery, Lindsay M, et al.
Publicado: (2020)

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)
por: Sader, Helio S., et al.
Publicado: (2023)

In vitro activity of aztreonam–avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019–2021
por: Wise, Mark G., et al.
Publicado: (2023)

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes
por: Trout, Robert E., et al.
Publicado: (2021)

Crystal structures of anhydrous and hydrated ceftibuten
por: Nisbet, Matthew L., et al.
Publicado: (2022)

1223. In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales from ICU and Non-ICU Wards Collected in Latin America and Globally as part of the ATLAS Surveillance Program 2017-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

1594. Antimicrobial Resistance Monitoring through the ATLAS Global Surveillance Program 2012-2018
por: Hackel, Meredith, et al.
Publicado: (2020)

Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa causing infection in Africa and the Middle East: a surveillance study from the ATLAS programme (2018–20)
por: Karlowsky, James A, et al.
Publicado: (2022)

2376. In Vitro Activities of Ceftaroline and Comparator Agents Against Bacterial Pathogens Collected From Patients With Skin and Skin Structure Infections in Latin America: AWARE Surveillance Program 2017
por: Hackel, Meredith, et al.
Publicado: (2018)

1452. Molecular Profile of β-Lactamase Genes and Siderophore-Dependent Iron Transporter Genes of Cefiderocol High MIC Isolates from SIDERO-WT Studies
por: Yamano, Yoshinori, et al.
Publicado: (2020)

1687. Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021)
por: Sader, Helio S, et al.
Publicado: (2022)

2153. Addition of Relebactam Increases Susceptibility to Imipenem Alone against Class C β-lactamase-Positive Enterobacterales: Asia/Pacific SMART 2019-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

Epidemiology of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacterales in US children, 2016–2020
por: Grome, Heather, et al.
Publicado: (2023)

Reviving the role of mecillinam against extended spectrum beta-lactamase producing enterobacterales
por: Kaleem, Fatima, et al.
Publicado: (2022)

Epidemiology of extended-spectrum β-lactamases in Enterobacterales in Taiwan for over two decades
por: Chao, Chien-Ming, et al.
Publicado: (2023)

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
por: Hackel, Meredith A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q4au29f67fqu0noj26spmovbrm